News & Events

Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer’s Disease

Halle (Saale) / Munich, Germany December 22, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]

Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress

HALLE (SAALE) / MUNICH, GERMANY, November 4, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development […]

Vivoryon Therapeutics N.V. to Report Third Quarter 2021 Financial Results on November 4, 2021

Halle (Saale) / Munich, Germany, November 1, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]

Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease

This announcement contains Inside Information as defined under the Market Abuse Regulation (EU) No. 596/2014 Halle (Saale) / Munich, Germany October 18, 2021 – Vivoryon Therapeutics N.V. […]

Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress

Strategic regional licensing partnership with Simcere Pharmaceutical Group to treat AD in Greater China US Phase 2 VIVA-MIND study for varoglutamstat in AD initiated as planned […]

Vivoryon Therapeutics N.V. to Publish its Financial Results for H1 2021 and Operational Progress

Halle (Saale) / Munich, Germany, September 14, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on discovery and development of […]

Vivoryon Therapeutics Provides Update on Financial Guidance

Halle (Saale) / Munich, Germany, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based […]

Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer’s Disease in Greater China

Halle (Saale) / Munich, Germany and Nanjing, China, June 29, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing […]

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small […]